ORIGIO A/S - CVR: 10975077

2021, DKK

28.04.2023

Bruttoresultat

151''

Primær drift

37.169'

Årets resultat

-112''

Aktiver

515''

Kortfristede aktiver

325''

Egenkapital

288''

Afkastningsgrad

7 %

Soliditetsgrad

56 %

Likviditetsgrad

143 %

Resultat

28.04.2023

Årsrapport	2021 28.04.2023	2020 11.01.2022	2019 11.01.2021	2018 31.03.2020	2017 30.04.2019	2016 28.03.2018	2015 31.03.2017
Nettoomsætning	929.787.000	909.643.000	808.132.000	997.951.000	746.062.000	847.330.000
Bruttoresultat	150.748.000	185.823.000	171.775.000	237.575.000	233.194.000	142.580.000	136.435.000
Resultat af primær drift	37.169.000	60.982.000	27.864.000	86.421.000	101.384.000	22.198.000	18.229.000
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0
Finansielle indtægter	1.528.000	9.929.000	9.609.000	10.797.000	20.106.000	13.500.000	20.988.000
Finansieringsomkostninger	-31.475.000	-3.536.000	-657.000	-445.000	-4.267.000	-2.330.000	-1.365.000
Andre finansielle omkostninger	0	0	0	0	-4.267.000	-2.330.000	-1.365.000
Resultat før skat	12.408.000	51.375.000	15.100.000	96.773.000	84.023.000	33.368.000	37.852.000
Resultat	-111.707.000	36.973.000	7.202.000	84.904.000	74.638.000	34.342.000	44.402.000
Forslag til udbytte	0	-30.000.000	-100.000.000	0	-130.000.000	0	0

Aktiver

28.04.2023

Årsrapport	2021 28.04.2023	2020 11.01.2022	2019 11.01.2021	2018 31.03.2020	2017 30.04.2019	2016 28.03.2018	2015 31.03.2017
Kortfristede varebeholdninger	0	17.193.000	30.849.000	47.100.000	153.554.000	175.690.000	87.500.000
Kortfristede tilgodehavender fra salg og tjenesteydelser	238.558.000	227.498.000	259.735.000	285.800.000	195.325.000	175.755.000	41.936.000
Likvider	86.642.000	24.516.000	43.145.000	27.275.000	12.791.000	0	17.606.000
Kortfristede aktiver	325.200.000	269.207.000	333.729.000	360.175.000	361.670.000	351.445.000	147.042.000
Immaterielle aktiver og goodwill	4.054.000	1.889.000	3.029.000	3.658.000	87.770.000	107.743.000	115.622.000
Finansielle anlægsaktiver	184.561.000	198.799.000	261.519.000	239.789.000	211.689.000	251.588.000	240.106.000
Materielle aktiver	764.000	56.330.000	68.054.000	78.023.000	81.906.000	85.469.000	86.241.000
Langfristede aktiver	189.379.000	257.018.000	332.602.000	321.470.000	381.365.000	444.800.000	441.969.000
Aktiver	514.579.000	526.225.000	666.331.000	681.645.000	743.035.000	796.245.000	589.011.000

Aktiver

28.04.2023

Passiver

28.04.2023

Årsrapport	2021 28.04.2023	2020 11.01.2022	2019 11.01.2021	2018 31.03.2020	2017 30.04.2019	2016 28.03.2018	2015 31.03.2017
Forslag til udbytte	0	30.000.000	100.000.000	0	130.000.000	0	0
Egenkapital	287.538.000	429.245.000	502.520.000	495.318.000	540.415.000	465.777.000	438.225.000
Hensatte forpligtelser	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	959.000	712.000	1.870.000
Leverandører af varer og tjenesteydelser	7.433.000	13.913.000	15.890.000	17.621.000	29.561.000	39.001.000	17.036.000
Kortfristede forpligtelser	227.041.000	96.980.000	163.811.000	186.327.000	165.098.000	329.756.000	148.916.000
Gældsforpligtelser	227.041.000	96.980.000	163.811.000	186.327.000	202.620.000	329.756.000	150.786.000
Forpligtelser	227.041.000	96.980.000	163.811.000	186.327.000	202.620.000	329.756.000	150.786.000
Passiver	514.579.000	526.225.000	666.331.000	681.645.000	743.035.000	796.245.000	589.011.000

Passiver

28.04.2023

Nøgletal

28.04.2023

Årsrapport	2021 28.04.2023	2020 11.01.2022	2019 11.01.2021	2018 31.03.2020	2017 30.04.2019	2016 28.03.2018	2015 31.03.2017
Afkastningsgrad	7,2 %	11,6 %	4,2 %	12,7 %	13,6 %	2,8 %	3,1 %
Dækningsgrad	16,2 %	20,4 %	21,3 %	23,8 %	31,3 %	16,8 %	Na.
Resultatgrad	-12,0 %	4,1 %	0,9 %	8,5 %	10,0 %	4,1 %	Na.
Varelagerets omsætningshastighed	Na.	52,9	26,2	21,2	4,9	4,8	Na.
Egenkapitals-forretning	-38,8 %	8,6 %	1,4 %	17,1 %	13,8 %	7,4 %	10,1 %
Payout-ratio	Na.	81,1 %	1.388,5 %	Na.	174,2 %	Na.	Na.
Gældsdæknings-nøgletal	118,1 %	1.724,6 %	4.241,1 %	19.420,4 %	2.376,0 %	952,7 %	1.335,5 %
Soliditestgrad	55,9 %	81,6 %	75,4 %	72,7 %	72,7 %	58,5 %	74,4 %
Likviditetsgrad	143,2 %	277,6 %	203,7 %	193,3 %	219,1 %	106,6 %	98,7 %

Resultat

28.04.2023

Gæld

28.04.2023

Årsrapport

28.04.2023

Nyeste:01.11.2021- 31.10.2022(offentliggjort: 28.04.2023)

Information om virksomhedens regnskabsklasse:The annual report for Origio A/S is presented in accordance with those regulations of the Danish Financial Statements Act concerning companies identified as class C enterprises (large enterprises). The accounting policies used are unchanged compared to last year, and the annual accounts are presented in Danish kroner (DKK). As of 1 November 2020 the sister company Kivex Biotec A/S merged with Origio A/S with Origio A/S as the continuing company. The merger was recognised using the book value-method. The comparative figures have not been restated, du to that the book value method has been used. .

Oplysning om pantsætninger og sikkerhedsstillelser:19. Contractual obligations, contingencies, etc. Contractual obligations The Company has entered into operating leases at the following amounts: The remaining term of the leases is 8 months with an average monthly lease payment of DKK 207 thousand, totalling DKK 2.375 thousand. Joint taxation The company acts as administration company for the group of companies subject to the Danish scheme of joint taxation and is unlimitedly, jointly, and severalle liable, along with the other jointly taxed companies, to pay the total corporation tax. The company is unlimited jointly and severally liable with the other jointly taxed companies for any obligation to withhold tax on interest, royalties and dividends. The liability relating to obligations in connection with withholding tax on dividends, interest, and royalties represents an estimated maximum of DKK 0 thousand. Any subsequent adjustments of corporate taxes or withholding taxes, etc., may cause changes in the company's liabilities. Contingent liabilties The Company is a party to a lawsuit with it's former landlord. In Management's opinion, apart from the liabilities recognised in the balance sheet at 31 December 2022, the outcome of these lawsuits will not affect the Company's financial position.

Beretning

28.04.2023

Dato for ledelsens godkendelse af årsrapporten:2023-04-25

Beskrivelse af usikkerhed ved indregning eller måling:Uncertainties as to recognition or measurement Determining the carrying amounts of certain assets and liabilities requires an estimate of how future events will affect the value of these assets and liabilities at the balance sheet date. Estimates that are material to the financial statements are made regarding measurement of equity investments in group companies and uncertain tax positions. The estimates are based on assumptions that management believes are reasonable but which are inherently uncertain and unpredictable. The assumptions may be incomplete or inaccurate, and unexpected events or circumstances may occur. The Company is also subject to risks and uncertainties that may cause actual results to differ from these estimates. The impairment assessment of investments in group companies are based on expectations of future cash flows of the individual companies. The assessment requires the establishment of assumptions and estimates of future cash flows and discount rate (WACC). The assessment of uncertain tax positions is based on determine whether it is probable that a benefit may be recognized and measure the amount of the benefit based on the probability of different outcomes.

Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen:Business review ORIGIO will continue its focus to further grow and strengthening the strong position in offering best in class products, driving and evolving innovation in line with customer needs. The collaboration within the CooperSurgical Companies and trusted partnerships open doors to extensive possibilities for the future. ORIGIO’s income statement for the year ending October 31, 2022 shows a net loss of DKK -111. 707 thousand and total assets of DKK 514. 580 thousand as of October 31, 2022, and total equity of DKK 287. 538 thousand. We operated in markets affected by COVID-19 but we have gained momentum and management is satisfied with the result for the year.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The supervisory board and the executive board have today discussed and approved the annual report of Origio A/S for the financial year 1 November 2021 - 31 October 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:The principal activities of the company ORIGIO has since 2012 been part of the CooperSurgical Companies. CooperSurgical Fertility Solutions is the global leader in IVF (In Vitro Fertilisering) and reproductive genetics, providing innovative products and services for every step in the ART journey (Assisted Reproductive Technology). Our company vision is a world with healthy women, babies and families. ORIGIO A/S was established in 1987 and has been a global leader in delivering innovative ART solu- tions. Combining the scientific knowledge with the CooperSurgical fertility companies ORIGIO, Research Instrument, The Pipette Company, K-Systems, and Wallace offer a broad range of trusted sys- tems of consumables, equipment, and technologies for a complete IVF process. In 2016 Reprogenetics, Recombine and Genesis Genetics joined the CooperSurgical family, and repre- sented the pioneers and global leaders of comprehensive reproductive genetic testing. As CooperGenomicsSM, they are the premier provider of genetic testing for every step of the family planning journey. Our combined product range includes pipettes, media and andrology products, and dedicated ART equipment, as well as state-of-the art electronic witnessing system. Our broad portfolio of products and services are being developed jointly in partnerships with experts and clinics across the globe to improve the ART solutions. Our industry-leading ART development program includes 7 Centers of Excellence around the world as well as collaboration with our external partners’ training facilities, such as the Center of Reproductive Medicine at the Vrije Universiteit Brussel in Brussels. We offer a wide range of courses and workshops for embryologists, gynecologists, lab managers and R&D scientists at every level of experience, with hands-on expert training in breakthrough technologies and next-generation techniques. Our team of experienced embryologists also assists customers with the establishment of clinics (turn-key projects), laboratory design, and clinic audits to optimize lab performance. In addition, they give lectures, run seminars and workshops, and support the research and development of new products.